Ogaki Kyoritsu Bank
VC Fund
Ogaki, Japan
Ogaki Kyoritsu Bank is a VC fund in Ogaki focused on Financial Services and Finance. The Ogaki Kyoritsu Bank, Ltd. is a Japan-based regional bank. The Bank operates in two segments. The Banking segment is engaged in the provision of various financial commodities and services, including deposit business, lending business, domestic and foreign exchange business, government bonds, investment trust funds, insurance and bonds, as wellas registration services; the marketable securities and investments business, as well as the collection and provision of information. The Leasing segment provides leasing services. In addition, the Bank is also engaged in the computer-related, think tanks, credit guarantee, credit cards and venture capital businesses, as well as the integrated processing of banking business, scrutiny and organize business of cash, document creation and storage business, and Real Estate collateral research and evaluation work.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ogaki Kyoritsu Bank invests in
Stages Ogaki Kyoritsu Bank invests in
Countries Ogaki Kyoritsu Bank invests in
Round sizes
Round size
- Seed
- $276k–$16M
- Series C
- $6.8M–$950M
Investment Focus
Industry
- Financial Services 4 (17%)
- Finance 3 (13%)
- Task Management 3 (13%)
- Medical 2 (8%)
- Internet 2 (8%)
Stage
- Funding Round 11 (46%)
- Seed 3 (13%)
- Series C 3 (13%)
- Debt Financing 2 (8%)
- Series A 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AEC Corporation
|
AEC Corporation is a company that operates the 24-hour unmanned fitness gym chain ECOFIT24. | $2.2M / Debt Financing / Dec 24, 2025 | |
FiberCraze
|
FiberCraze is a manufacturing company that specializes in the development and sales of thread materials. | $276.1K / Seed / Aug 10, 2023 | |
iBody
|
iBody is a venture from Nagoya University Graduate School of Life and Agriculture.We will contribute to the improvement of treatment and diagnostic technology and the development of life science by using monoclonal antibody excavation technology from a small amount of blood, and contribute to the improvement of human health and quality of life. | $21.3M / Jul 31, 2020 | |
Photo Electron Soul
|
Photo electron Soul mission is to innovate the world of "seeing (fine observation)" and "creating (fine processing)" through the development of photocathode electron beam technology. The photocathode electron beam technology developed by our company will produce next generation electron beams with high performance andversatility (pulse structure, low dispersion, large current). By renewing the electron beam, which is a key device for industrial equipment such as electron microscopes, semiconductor device manufacturing / inspection equipment, and metal 3D printers, it is possible to realize fine observation, fine processing, high throughput, etc. Breakthroughs in a wide range of fields such as science, materials, and electronics. | $87.9M / Jul 17, 2020 | |
|
Photo Electron Soul
|
Photo electron Soul mission is to innovate the world of "seeing (fine observation)" and "creating (fine processing)" through the development of photocathode electron beam technology. The photocathode electron beam technology developed by our company will produce next generation electron beams with high performance andversatility (pulse structure, low dispersion, large current). By renewing the electron beam, which is a key device for industrial equipment such as electron microscopes, semiconductor device manufacturing / inspection equipment, and metal 3D printers, it is possible to realize fine observation, fine processing, high throughput, etc. Breakthroughs in a wide range of fields such as science, materials, and electronics. | $87.9M / Debt Financing / Jul 17, 2020 | |
U-MaP
|
U-MaP is an “industrial materials” venture from Nagoya University, which was established mainly by researchers at Nagoya University. The mission under the company name is "Providing new solutions to society through technological innovation through ultimate materials and processing technologies (Ultimate Material and Processing)." Underthis mission, U-MaP will continue to commercialize university technology seeds and create next-generation industries. | $2.8M / Venture - Series Unknown / Jun 19, 2020 | |
Techno-Speech
|
Techno-Speech creates creative speech and singing synthesis technologies for use in information and announcing systems. Their speech-related technology seems to be more human-like than conventional technology because it uses artificial intelligence to provide rich emotional expression and gives people access to voice services whenever they needthem at a suitable rate. | Seed / May 28, 2020 | |
PD AeroSpace
|
PD AeroSpace is a space development of a "fully reusable sub-orbital spacecraft" that can reach an altitude of 100km Use for space travel, experiments using the space environment, etc.PD AeroSpace provide technical support for customer's new product development and new business development. | $931.5K / Series A / Apr 17, 2020 | |
Kringle Pharma
|
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumorcells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan. | $104.9M / Apr 04, 2020 | |
|
Kringle Pharma
|
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumorcells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan. | $6.8M / Series C / Mar 02, 2020 | |
| See all 24 investments → | |||
Co-Investors
Dai-ichi Life
4 deals together
Juroku Lease
4 deals together
Juroku Bank
3 deals together
Nippon Venture Capital
3 deals together
Shoko Chukin Bank
3 deals together
SMBC Venture Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Ogaki Kyoritsu Bank invest in?
Ogaki Kyoritsu Bank invests primarily in Financial Services, Finance and Task Management startups, most often at Funding Round and Seed stage. Most of the 24 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ogaki Kyoritsu Bank's check size?
Ogaki Kyoritsu Bank typically joins rounds of $276k–$16M at Seed and $6.8M–$950M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ogaki Kyoritsu Bank participates in.
When did Ogaki Kyoritsu Bank last invest?
The most recent investment recorded for Ogaki Kyoritsu Bank closed in Dec 2025. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
